ONCAlert | 2017 San Antonio Breast Cancer Symposium

Results for Ipilimumab and Nivolumab Following Autologous Stem Cell Transplant in Multiple Myeloma

Andrew L. Pecora, MD
Published Online:2:03 PM, Wed January 10, 2018

Andrew L. Pecora, MD, President of the Physician Services Division and Chief Innovation Officer at Hackensack Meridian Health, discusses preliminary safety and efficacy data for combined checkpoint inhibition with ipilimumab (Yervoy) and nivolumab (Opdivo) as consolidation therapy following autologous stem cell transplant in patients with multiple myeloma and non-Hodkin lymphoma.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.